← Back to Browse

Entero Therapeutics, Inc.

ENTO • Healthcare

⇄ Compare
19
Grade F
Compass

About Entero Therapeutics, Inc.

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases.

Current Price
$2.85
Market Cap
$14M

Quality Assessment

Entero Therapeutics, Inc. is a high-risk healthcare company with a Compass Score of 19. Poor quality metrics and high risk. Not one for conservative investors.

Score Breakdown

The Compass Score is based on 6 quality factors identified by academic research.

Click any factor to see detailed metrics

Valuation Metrics

Click any metric for details

Fair Value

Pro

See whether this stock trades above or below its fair value.

Catalyst Signal

Plus

Recent earnings beats and analyst-upgrade momentum. How it works

Catalyst Score
🔒
EPS Beat Streak
🔒
Net Upgrades (180d)
🔒

See recent earnings beats and analyst-upgrade momentum.

Analyst Track Record

Plus

See each covering analyst's historical hit rate.

Financial Health

Plus

Click any metric for details

See bankruptcy-risk and financial-strength scores for this company.

Growth Projections

Plus
Projected EPS Growth
🔒
Projected Revenue Growth
🔒

See projected EPS and revenue growth for this company.

Technical Overview

Click any metric for details

Similar High-Quality Stocks

CPIX

Cumberland Pharmaceuticals Inc.

34
$5.93
Grade D

TXMD

TherapeuticsMD, Inc.

34
$2.00
Grade D

LFCR

Lifecore Biomedical, Inc.

32
$4.75
Grade D

ADPT

Adaptive Biotechnologies Corporation

31
$21.06
Grade D

DRIO

DarioHealth Corp.

31
$7.22
Grade D

ASRT

Assertio Holdings, Inc.

30
$23.50
Grade D

Important Disclaimer

The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.